




CLINICAL EVIDENCE SUGGESTS INCREASED EFFICACY WHEN RADIOTHERAPY IS COMBINED WITH DRUGS FOR METASTATIC CANCER

Months of Progression Free or Overall Survival

— = control



Design	LAT vs. maintenance in oligometastatic NSCLC	SBRT vs. palliative tx in oligometastatic cancer	Pembro after LAT in oligometastatic NSCLC	Pembro and multi-site SBRT in advanced cancer	TKI after SBRT in EGFRm oligometastatic NSCLC
Phase	Ph. II RCT	Ph. II RCT	Ph. II single-arm	Ph. II single-arm	Ph. III RCT
N	49	99	51	79	136
RT	1.32 mets	1.67 mets	1.49 mets	1.66 mets	2.8 mets

¹Gomez, Daniel R., et al. Journal of Clinical Oncology, vol 37, no. 18, 2019. | ²Palma, David A., et al. The Lancet Oncology, vol 393(10185), 2019. | ³Bauml, Joshua M., et al. JAMA Oncology, 2019. | ⁴Luke, Jason J., et al. Journal of Clinical Oncology, vol. 36, no. 16, 2018. | ⁵Wang XS, Zeng M. Journal of Clinical Oncology, vol 38, no 15, 2020.